Business Wire - First Horizon Pharmaceutical Corporation Announces Appointments to the Board of Directors and Scientific Advisory Board
Business Editors
ROSWELL, Ga.–(BUSINESS WIRE)–March 1, 2000
First Horizon Pharmaceutical(TM)Corporation, an emerging pharmaceutical company, announced today the appointment of John E. Robson and Jon S. Saxe to the Board of Directors and the appointment of Nelson L. Levy, Ph.D., M.D. to the Scientific Advisory Board.
“We are very excited to have John Robson and Jon Saxe join the Board of Directors. Both executives have extensive experience in licensing and development and have occupied integral positions contributing to the growth of companies like Searle, Hoffmann LaRoche and Protein Design Labs, Inc.,” said Mahendra Shah, Chairman and CEO, “Furthermore, we welcome the invaluable opportunity to work with Dr. Levy as a member of our Scientific Advisory Board. His wealth of expert knowledge in product development will be essential to our future growth.”
Related Results
Boehringer, Abbott to co-promote Flomax - Brief Article
At work with… Stephen Neale
FDA Approves Three Hypertension Treatments.(Brief Article)(Statistical Data I…
Novartis settles dispute with FTC.(Brief Article)
FTC to Investigate Possible Pharma Collusion.(payoffs for delays of generic d…
Jon S. Saxe serves as a Director for Protein Design Labs, Inc., Questcor Pharmaceuticals Inc., Incyte Pharmaceuticals Inc., ID Biomedical Corporation, InSite Vision, and is Chairman of POINT Biomedical Corporation and Iconix Pharmaceuticals. His expansive background includes executive positions within the biotechnology and pharmaceutical industries. Mr. Saxe received his B.S. Ch.E. degree from Carnegie-Mellon University, a J.D. from George Washington University School of Law and his L.L.M. from New York University School of Law.
John E. Robson is an investment banker with Robertson Stephens, where he is Senior Advisor. Previously, he was President and Chief Executive Officer of G.D. Searle & Company and a Director of Chiron Corp., a major biotechnology company. Mr. Robson has held presidential appointments in Washington, D.C., and was Deputy Secretary of the United States Treasury Department during the Bush Administration. He is currently a Director of Exide Corp., Monsanto Company, Northrop Grumman Corp. and Prologis Trust. He received a B.A. degree from Yale University and a J.D. from Harvard University Law School.
Nelson L. Levy, Ph.D., M.D., is currently the CEO of the CoreTechs Corporation. He was previously the President of Fujisawa Pharmaceutical Company and Vice President for Pharmaceutical Research at Abbott Laboratories, where he was instrumental in the development of Biaxin, Hytrin and Zileuton. He is the author of over 130 scientific publications. Dr. Levy was graduated summa cum laude from Yale University, obtained his M.D. from Columbia University and his Ph.D. in Immunology from Duke University.
First Horizon Pharmaceutical(TM) Corporation is an emerging pharmaceutical company focused on the development and marketing of branded prescription pharmaceuticals for the treatment of chronic diseases. The Company currently markets 11 prescription products to high prescribing physicians throughout the United States through its nationwide sales and marketing force of 130 individuals. First Horizon’s key products include Nitrolingual(R) Pumpspray, Robinul(R), Robinul(R) Forte, Tanafed(R) and Zebutal(TM).
COPYRIGHT 2000 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
